Evidence map›Paper›PMID 31238077›Full record

ReviewExperimental eye research2019

Corneal injury: Clinical and molecular aspects.

Brayden Barrientez, Sarah E Nicholas, Amy Whelchel, Rabab Sharif, Jesper Hjortdal, Dimitrios Karamichos

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Experimental eye research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06854393 (Lacripep, a Novel Investigational Agent, for Corneal Wound Healing and Ocular Surface Homeostasis), which is not on this map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06854393 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Lacripep, a Novel Investigational Agent, for Corneal Wound Healing and Ocular Surface Homeostasis

TypeinterventionalSponsorHenry M. Jackson Foundation for the Advancement of Military MedicineRan2025 to 2027Enrolled88ConditionsCorneal Epithelial Wound HealingArms0.00025% Lacripep ophthalmic solution and Placebo
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.Translational vision science & technology · 2026
    Article
  11. Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Brayden BarrientezDepartment of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Sarah E NicholasDepartment of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Amy WhelchelDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Rabab SharifDepartment of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Jesper HjortdalDepartment of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.
Dimitrios KaramichosDepartment of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. Electronic address: Dimitrios-Karamichos@ouhsc.edu.
University of Oklahoma Health Sciences Center · USDean McGee Eye Institute · USAarhus University Hospital · DK

Funding

Sex Hormones and KeratoconusR01EY028888 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI KARAMICHOS, DIMITRIOS · 2018 to 2020
$1.1M
NEI NIH HHS R01 EY028888
6 · The paper itself

Abstract

Currently, over 10 million people worldwide are affected by corneal blindness. Corneal trauma and disease can cause irreversible distortions to the normal structure and physiology of the cornea often leading to corneal transplantation. However, donors are in short supply and risk of rejection is an ever-present concern. Although significant progress has been made in recent years, the wound healing cascade remains complex and not fully understood. Tissue engineering and regenerative medicine are currently at the apex of investigation in the pursuit of novel corneal therapeutics. This review uniquely integrates the clinical and cellular aspects of both corneal trauma and disease and provides a comprehensive view of the most recent findings and potential therapeutics aimed at restoring corneal homeostasis.

Indexed as

Corneal DiseasesCorneal InjuriesCorneal TransplantationHumansOphthalmologic Surgical ProceduresStem Cell TransplantationCorneal traumaDiabetic keratopathyFuchs' dystrophyKeratoconusRegenerative medicine

Identifiers

PMID31238077
PMCPMC6703935
OpenAlexW2952772985

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.